Advances in Stereotactic Body Radiotherapy for Ultra-Central Lung Tumors
Author Information
Author(s): Viola Salvestrini, Andrea Lastrucci, Marco Banini, Mauro Loi, Maria Grazia Carnevale, Emanuela Olmetto, Pietro Garlatti, Gabriele Simontacchi, Giulio Francolini, Pierluigi Bonomo, Yannick Wandael, Isacco Desideri, Renzo Ricci, Daniele Giansanti, Vieri Scotti, Lorenzo Livi, Mark D. De Ridder
Primary Institution: Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
Hypothesis
Can stereotactic body radiotherapy (SBRT) be safely and effectively used for ultra-central lung tumors?
Conclusion
Stereotactic body radiotherapy for ultra-central lung tumors shows promising results with acceptable toxicity when patient selection and dosimetry constraints are carefully managed.
Supporting Evidence
- Recent studies show that SBRT can be effective for ultra-central lung tumors.
- The SUNSET trial demonstrated that a specific dose regimen is feasible with acceptable toxicity.
- Patient selection and follow-up are critical for successful outcomes.
- Retrospective data indicate varying outcomes and toxicity rates.
- Prospective studies are limited but suggest promising results.
Takeaway
Doctors are finding new ways to use radiation therapy for hard-to-treat lung tumors, and it can be safe if done carefully.
Methodology
The review summarizes recent studies and proposes a workflow for treating ultra-central lung tumors with SBRT.
Potential Biases
Potential reporting bias regarding cardiac toxicity and non-cancer-related mortality.
Limitations
The literature is mostly retrospective and lacks consensus on definitions and treatment protocols.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website